Difference between revisions of "Selpercatinib (Retevmo)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 35: | Line 35: | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
| − | [[Category:EMA approved in | + | [[Category:EMA approved in 2020]] |
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 22:47, 8 November 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, LOXO-292 selectively binds to and targets various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity.
Diseases for which it is used
- RET-positive NSCLC
- RET-mutant medullary thyroid cancer
- RET-positive thyroid cancer
- RET+ solid tumors (tissue-agnostic)
History of changes in FDA indication
Non-small cell lung cancer
- 5/8/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Based on LIBRETTO-001)
- 9/21/2022: Granted regular approval for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion. (Based on LIBRETTO-001)
RET (tissue-agnostic)
- 9/21/2022: Granted accelerated approval for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. (Based on LIBRETTO-001)
Thyroid cancer
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Based on LIBRETTO-001)
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Based on LIBRETTO-001)
History of changes in EMA indication
- 2/11/2021: Initial marketing authorization as Retsevmo.
Also known as
- Code name: LOXO-292
- Brand names: Retevmo, Retsevmo